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INTRODUCTION 
    Epilepsy is a disorder that is best viewed as a symptom of disturbed electrical activity 
in the brain caused by a wide variety of etiologies.  It is a collection of many different types 
of seizures that vary widely in severity, appearance, cause , consequences, and management.   
   (1) Epilepsy is a common medical and social disorder or group of disorders with 
unique characteristics .The word “epilepsy” is derived from latin and Greek words for “ 
seizures “ or “ to seize upon”.  
   Epilepsy has been reported to affect between 5 to 10 people per 1000 and the 
incidence in developed countries is around 50/100,000/year. It is estimated that 30% of those 
with epilepsy have recurrent seizures despite optimal antiepileptic therapy. 
   An epileptic seizure is a transient paroxysm of uncontrolled discharges of neurones 
causing an event that is discernible by the person experiencing the seizure or by an observer. 
The tendency to have recurrent attacks is known as epilepsy; by definition, a single attack 
does not usually constitute epilepsy. Epileptic seizures or attacks are a symptom of many 
different diseases, and the term epilepsy is loosely applied to a number of conditions that 
have in common a tendency to have recurrent epileptic attacks.  
   A patient with epilepsy will show recurrent epileptic seizures that occur unexpectedly 
and stop spontaneously. Epilepsy is also remarkably uniformly distributed around the world. 
There are no racial, geographical or social class boundaries. It occurs in both sexes, at all 
ages, especially in childhood, adolescence and increasingly in ageing populations. The 
periodic clinical features of seizures are often dramatic and alarming, and frequently elicit 
fear and misunderstanding. This in turn has led to profound social consequences for sufferers, 
which has greatly added to the burden of this disease(2). 
   In ancient times, epileptic attacks were thought to be the result of invasion and 
possession of the body by supernatural forces, usually malign or evil influences, requiring 
exorcism, incantations or other religious or social approaches. Today, seizures are viewed as 
electromagnetic discharges in the brain in predisposed individuals, attributable in part to 
putative genetic factors, underlying neurological disorders, and largely unknown 
neurochemical mechanisms.  
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             A wide range of different seizure types and epilepsy syndromes have been identified. 
Patients are now treated with pharmacotherapy, occasionally with neurosurgical techniques, 
as well as with psychological and social support. Epilepsy has many causes, but in most 
patients a cause cannot be identified. Among the pathologies most commonly considered to 
give rise to epilepsy are cerebrovascular lesions, perinatal or postnatal trauma, infections of 
the CNS, and tumours or congenital malformations of the brain. This area is referred to as the 
epileptogenic lesion. The epileptogenic zone is where the seizures actually begin, and this 
area is usually in or near the epileptogenic lesion. The function of nerve cells and their 
circuits in the epileptogenic zone has been fundamentally altered, and some even destroyed, 
by the pathology.   
       During an epileptic seizure, neurons in the epileptogenic zone begin to discharge 
hypersynchronous electrical signals at an excessively high rate or in an abnormal pattern. An 
epileptic seizure can originate only in structures of the brain (e.g. the cerebral cortex and 
amygdala) but the seizure may then spread to other structures of the CNS (e.g. the basal 
ganglia). Once a patient has developed epilepsy, individual seizures may be precipitated by a 
number of conditions and circumstances. 
EPIDEMIOLOGY 
      WHO and International League against Epilepsy (ILAE) have estimated that 34 
million out of 50 million people with epilepsy live in developing countries and nearly 80% of 
them are not on treatment.  It is estimated that in India with a population of over 1.5 billion 
there will be around 6-10 million people with epilepsy, accounting for nearly 1/5th of global 
burden. The paucity of medical infrastructure, economic concerns and socio-cultural attitudes 
are known to be a hindrance to the optimal care of epilepsy in these countries.(4) 
      Neuroepidemiology is the study of the distribution and determinants of neurological 
diseases in human population . While the clinician is concerned with disease in the individual 
patient, the epidemiologist is concerned with the occurrence of disease within a community. 
Epidemiological information benefits health policy-makers, public health officials, medical 
practitioners and patients, the pharmaceutical industry and other epidemiologists. 
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AETIOLOGY 
Epileptic seizures are produced by abnormal discharges of neurones that may be 
caused by any pathological process which affects the cortical layer of the brain. The 
idiopathic are those in which there is a clear genetic component, and they probably account 
for a third of all new cases of epilepsy. In a significant proportion of cases, however, no cause 
can be determined and these are known as the cryptogenic epilepsies. Possible explanations 
for cryptogenic epilepsy include as yet unexplained metabolic or biochemical abnormalities 
and microscopic lesions in the brain resulting from brain malformation or trauma during birth 
or other injury. The term ‘symptomatic epilepsy’ indicates that a probable cause has been 
identified. The likely aetiology of epilepsy depends upon the age of the patient and the type 
of seizure. The commonest causes in young infants are hypoxia or birth asphyxia, intracranial 
trauma during birth, metabolic disturbances and congenital malformations of the brain or 
infection. 
 In young children and adolescents, idiopathic seizures account for the majority of the 
epilepsies, although trauma and infection also play a role. In this age group, particularly in 
children aged between 6 months and 5 years, seizures may occur in association with febrile 
illness. These are usually short, generalised tonic clonic convulsions that occur during the 
early phase of a febrile disease. They must be distinguished from seizures that are triggered 
by central nervous system infections which produce fever, for example, meningitis or 
encephalitis. Unless febrile seizures are prolonged, focal, recurrent or there is a background 
of neurological handicap, the prognosis is excellent and it is unlikely that the child will 
develop epilepsy. The range of causes of adult-onset epilepsy is very wide. Both idiopathic 
epilepsy and epilepsy due to birth trauma may also begin in early adulthood. Other important 
causes are head injury, alcohol abuse, cortical dysplasias, brain tumours and cerebrovascular 
diseases. Brain tumours are responsible for the development of epilepsy in up to a third of 
patients between the ages of 30 and 50 years. Over the age of 50 years, cerebrovascular 
disease is the commonest cause of epilepsy, and may be present in up to half of patients. 
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 CLASSIFICATION OF EPILEPSY(1) 
People with epilepsy have recurring seizures that often occur spontaneously and 
without warning. The official definition of a seizure is "a transient occurrence of signs and 
symptoms due to an abnormal, excessive or synchronous neuronal activity in the brain." 
  This means that during a seizure, large numbers of brain cells are activated 
abnormally at the same time. It is like an "electrical storm" in the brain. 
The nature of the seizures depend upon many factors, such as the person’s age, the 
sleep-wake cycle, prior injuries to the brain, genetic tendencies, medications, which circuits 
in the brain are involved, and many others. 
Separating seizures into different types helps guide further testing, treatment, and 
prognosis or outlook. Using a common language for seizure classification also makes it easier 
to communicate among clinicians caring for people with epilepsy and doing research on 
epilepsy. The classification also provides common words for people with epilepsy and the 
general public to describe seizures. The basic classification is a simple version of the major 
categories of seizures. The first step is to separate seizures by how they begin in the brain. 
   The classification begins by dividing seizures into those that start focally, meaning 
involving circuits (networks) in one hemisphere or side of the brain versus those that engage 
networks in both sides of the brain at the onset. 
    If onset is unknown, the seizure falls into the unknown onset category. Later on, the 
seizure type can be changed if the onset of a person’s seizures becomes clear. The type of 
seizure onset is important because it affects choice of seizure medication, possibilities for 
epilepsy surgery, outlook, and possible causes. 
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Describing motor and other symptons in focal seizures: Many other symptoms may 
occur during a seizure. In this basic system, seizure behaviors are separated into groups that 
involve movement. 
A focal motor seizure means some type of movement occurs during the event. For 
example, twitching, jerking, or stiffening movements of a body part or automatisms 
(automatic movements such as licking lips, rubbing hands, walking, or running). 
A focal non-motor seizure includes other symptoms such as changes in sensation, 
emotions, thinking, or experiences. A seizure therefore can be focal motor (the word “onset” 
is implied) or focal non-motor, for example, focal sensory, with or without mention of 
awareness.  It is also possible for a focal aware or impaired awareness seizure to be sub-
classified as motor or non-motor onset. 
Describing generalized onset seizures: Seizures that start in both sides of the brain, 
called generalized onset, can be motor or non-motor (absence).The generalized tonic-clonic 
seizure term is still used to describe seizures with stiffening (tonic) and jerking (clonic). This 
loosely corresponds to “grand mal.” 
  The generalized absence seizure corresponds to the old term “petit mal.” These 
seizures involve brief changes in awareness, staring, and some may have automatic or 
repeated movements like lipsmacking. 
 
 
 
                                                                                             Introduction  
 
A prospective, observational study on prevalence of cardiovascular risk factors and  
statin use in patients with epilepsy and  assessment of quality of life   6 
 
THE NEW EXPANDED CLASSIFICATION 
The expanded classification keeps the framework of the basic classification, but adds 
more seizure types as subheadings. 
 Focal motor onset seizure types include automatisms, atonic, clonic, epileptic spasm, 
hyperkinetic, myoclonic and tonic seizures. Several of these types also appear in the 
generalized onset categories.  
 Focal non-motor onset seizures include autonomic, behaviour arrest, cognitive, 
emotional, and sensory seizures. Since seizures often have several different symptoms 
and behavioural signs, the seizure is named for the first prominent symptom or sign. 
This has been the usual clinical practice, because seizure onset marks the part or 
network of the brain involved in generating the seizure. Other regions become 
involved as the seizure spreads. 
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Focal onset seizures may occur with or without impairment of awareness, except that 
atonic and epileptic spasm seizures usually do not show obvious impairment of awareness. 
 Focal automatisms seizure: A seizure with automatic fumbling behaviour, such as lip-
smacking, hand-rubbing, picking at objects, walking in circles, repeating meaningless 
phrases, or undressing. 
 Focal atonic seizure: Focal, for example in one arm or leg, sudden loss of muscle tone 
and strength, resulting in a transiently limp limb. 
 Focal clonic seizure: Sustained rhythmically jerking of one part of the body or face. 
 Focal epileptic spasms: Sudden flexion or bending of the trunk with flexion or 
extension of the limbs lasting less than a few seconds. These often occur in clusters. 
The term infantile spasm applies to epileptic spasms occurring during infancy. Video-
EEG monitoring and a brain MRI may be needed to determine whether onset of 
epileptic spasms is focal or generalized. 
 Hyperkinetic seizure: A seizure with vigorous thrashing or pedaling movements. Even 
though both sides of the body are usually involved with these seizures, the EEG often 
shows a focal and frontal lobe origin. Some people used to call these hypermotor 
seizures. 
 Focal myoclonic seizure: Irregular and brief lightning jerks of limbs or face on one 
side of the body. 
 Focal tonic seizure: Stiffening of arm, leg, or neck producing a forced posture during 
the seizure. 
 Focal autonomic seizure: A seizure whose primary effect is on autonomic nervous 
system functions, such as heart rate, blood pressure, sweating, skin colour, hair 
standing on end (piloerection), and gastrointestinal sensations. 
 Focal behaviour arrest seizure: In this seizure type, movement stops, sometimes called 
a freeze or a pause. Because brief behaviour arrest is common and hard to recognize 
as being abnormal, a seizure should only be classified as a focal behaviour arrest 
seizure if the behaviour arrest is the main feature through the entire seizure. 
 Focal cognitive seizure: This type of seizure refers to impaired cognition (thinking) 
during a seizure. The impairment might affect language, spatial perception, ability to 
calculate math, or other cognitive functions. Do not count loss of awareness or 
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memory (unless only memory is impaired) as a focal cognitive seizure, because 
awareness is used to describe other seizure types. 
 Focal emotional seizure: This seizure type begins with spontaneous fear, anxiety, or 
less often joy. There may be involuntary laughing or crying, each of which might or 
might not be accompanied by a subjective emotion. Gelastic and dacrystic seizures 
would fit into this group. 
 Focal sensory seizure: Sensory seizures can consist of tingling or numbness, visual 
symptoms, sounds, smells, tastes, tilting or spinning sensations (vertigo), and hot-cold 
feelings. 
Generalized onset seizures are not characterized by level of awareness, because 
awareness is almost always impaired. 
 Generalized tonic-clonic: Immediate loss of awareness, with stiffening of all limbs 
(tonic phase), followed by sustained rhythmic jerking of limbs and face (clonic 
phase). Duration is typically 1 to 3 minutes. The seizure may produce a cry at the 
start, falling, tongue biting, and incontinence. 
 Generalized clonic: Rhythmical sustained jerking of limbs and/or head with no tonic 
stiffening phase. These seizures most often occur in young children.    
 Generalized tonic: Stiffening of all limbs, without clonic jerking. 
 Generalized myoclonic: Irregular, unsustained jerking of limbs, face, eyes, or eyelids. 
The jerking of generalized myoclonus may not always be left-right synchronous, but 
it occurs on both sides. 
 Generalized myoclonic-tonic-clonic: This seizure is like a tonic-clonic seizure, but it 
is preceded by a few myoclonic jerks on both sides of the body. Such seizures are 
commonly seen in people with the syndrome of juvenile myoclonic epilepsy. 
 Generalized myoclonic-atonic: This seizure presents with a few myoclonic jerks, 
followed by a limp drop. These seizures may be seen in children with Doose 
syndrome. 
 Generalized atonic: This is an epileptic drop attack, with sudden loss of muscle tone 
and strength and a fall to the ground or a slump in a chair. Atonic seizures usually last 
only seconds. 
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 Generalized epileptic spasms: Brief seizures with flexion at the trunk and flexion or 
extension of the limbs. Video-EEG recording may be required to determine focal 
versus generalized onset. 
 Generalized typical absence: Sudden onset when activity stops with a brief pause and 
staring, sometimes with eye fluttering and head nodding or other automatic behaviors. 
If it lasts for more than several seconds, awareness and memory are impaired. 
Recovery is immediate. The EEG during these seizures always shows generalized 
spike-waves. 
 Generalized atypical absence: Like typical absence seizures, but may have slower 
onset and recovery and more pronounced changes in tone. Atypical absence seizures 
can be difficult to distinguish from focal impaired awareness seizures, but absence 
seizures usually recover more quickly and the EEG patterns are different. 
 Generalized myoclonic absence: A seizure with a few jerks and then an absence 
seizure. 
 Generalized eyelid myoclonia: Eyelid myoclonia represents jerks of the eyelids and 
upward deviation of the eyes, often precipitated by closing the eyes or by light. These 
may be associated with absence seizures in people with Jeavon’s syndrome. 
Unknown Onset Seizures 
 Clinicians using the classification will identify a seizure as focal or generalized onset 
if there is about an 80% confidence level about the type of onset. This means that there is 
significant confidence on the seizure onset and type. 
   Seizures without enough confidence about onset are labeled of unknown onset. The 
most important seizures of unknown onset are tonic-clonic, epileptic spasm, and behavior 
arrest (which could be either a focal impaired awareness or absence seizure).If a seizure onset 
becomes clarified at a later date, the type will change. 
DIAGNOSIS(5) 
Diagnosing epilepsy can be difficult as it is first necessary to demonstrate a tendency 
to recurrent epileptic seizures. The one feature that distinguishes epilepsy from all other 
conditions is its unpredictability and transient nature. The diagnosis of epilepsy is clinical and 
depends on a reliable account of what happened during the attacks, if possible both from the 
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patient and from an eyewitness. Investigations may help and the EEG is usually one of them. 
These investigations, however, cannot conclusively confirm or refute the diagnosis of 
epilepsy. There are other conditions that may cause impairment or loss of consciousness and 
which can be misdiagnosed as epilepsy; these include syncope, breath-holding attacks, 
transient ischaemic attacks, psychogenic attacks, etc. In addition, people may present with 
acute symptomatic seizures or provoked seizures as a result of other problems such as drug 
intake, metabolic dysfunction, infection, head trauma or flashing lights (photosensitive 
seizures). These conditions have to be clearly ruled out before a diagnosis of epilepsy is 
made. Epilepsy must only be diagnosed when seizures occur spontaneously and are recurrent. 
The diagnosis must be accurate since the label ‘suffering with epilepsy’ carries a social 
stigma that has tremendous implications for the person.  
The EEG is often the only examination required, particularly in generalised 
epilepsies, and it aims to record abnormalneuronal discharges. EEGs have, however, 
limitations that should be clearly understood. Up to 5% of people without epilepsy may have 
non-specific abnormalities in their EEG recording, while up to 40% of people with epilepsy 
may have a normal EEG recording between seizures. Therefore, the diagnosis of epilepsy 
should be strongly supported by a bona fide history of epileptic attacks. Nevertheless, the 
EEG is invaluable in classifying seizures. The chance of recording the discharges of an actual 
seizure during a routine EEG, which usually takes 20–30 min, is slight and because of this, 
ambulatory EEG monitoring and EEG video-telemetry are sometimes required. Ambulatory 
EEG allows recording in day-to-day circumstances using a small cassette recorder. EEG 
video-telemetry is useful in the assessment of difficult cases, particularly if surgery is 
considered. The person is usually admitted to hospital and remains under continuous 
monitoring. This is only helpful in a very few cases, and it is best suited for people who have 
frequent seizures.  
Neuroimaging with magnetic resonance imaging (MRI) is the most valuable 
investigation when structural abnormalities such as stroke, tumour, congenital abnormalities 
or hydrochephalus are suspected. MRI should be carried out in anyone presenting with partial 
seizures or where a structural lesion on the brain may be responsible for seizures. 
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MANAGEMENT 
    The main treatment goals of epilepsy are to achieve adequate seizure control and 
minimize side effects to anti-epileptic medications with much less attention being given in 
the past to the patient’s perception of the impact of the disease in everyday life. People with 
epilepsy face many challenges particularly in the psychosocial realm (anxiety, social stigma, 
low self esteem, difficulty in driving, unemployment), all of which can impact quality of life 
(QOL) 
    The best quality of life is associated with a seizure free state. However, a balance 
between efficacy and side effects must be reached. With older antiepileptic drugs (AEDs), 
less than 50% of patients achieve good seizure control. Moreover epilepsy being a chronic 
condition, the patient can develop significant side effects like sedation, impaired memory etc. 
Hence some seizure control may have to be sacrificed to improve functioning. The newer 
AEDs offer alternatives for balancing seizure frequency and drug side effects(1).  
    Providing optimal quality of life goes beyond balancing seizure control and side 
effects. It involves assessing all concerns of a person regarding issues such as driving, their 
future, social stigma etc. It is also important to treat the other associated comorbidities like 
depression, anxiety, neuropsychiatric conditions which can impact the overall Quality of life. 
General Approach to Treatment 
The following is the updated clinical guidance set by NICE Group (National Institute 
of Clinical Excellence), U.K regarding initiation of pharmacological therapy .(6) 
AED therapy should only be started once the diagnosis of epilepsy is confirmed. 
Treatment with AED is generally recommended after a second seizure except in conditions 
where the individual has a neurological deficit, the EEG shows unequivocal activity and a 
structural abnormality is seen in the brain. The decision to initiate AED therapy should be 
taken between the individual, their family (as appropriate) and the specialist after a full 
discussion of the risks and benefits of treatment which should take into account details of the 
individual’s epilepsy syndrome, prognosis and lifestyle.   
  It is recommended that individuals should be treated with a single antiepileptic drug 
(Monotherapy) wherever possible. If the initial treatment is unsuccessful, then monotherapy 
using a second drug can be tried. If an AED has failed due to adverse effects or continued 
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seizures, then a second drug is started (which is an alternative first line or second line drug) 
and built up to an adequate or maximum tolerated dose; then the first drug is slowly tapered. 
  It is recommended that combination therapy (adjunctive or add on therapy) should 
only be considered when attempts at monotherapy with AEDs have failed. Combination of 
drugs with different mechanisms of action is considered advantageous. 
Antiepileptic drugs used commonly. 
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ASSESSMENT OF CARDIOVASCULAR RISK AND STATIN USE 
Some studies have tried to identify an association between CVRFs and epilepsy, 
however the results and observations have been inconsistent. 
Statins are the most popular cholesterol-lowering agents and can be beneficial in the 
treatment of hypercholesterolemia and other related diseases. Statins act by reducing the 
hepatic cholesterol biosynthesis and upregulation of LDL-C receptors on the surface of 
hepatocytes, which then leads to enhanced removal of LDL-C from circulation. Statins also 
exert pleiotropic actions such as reducing the accumulation of esterified cholesterol into 
macrophages, increasing endothelial nitric oxide synthetase, decreasing inflammation, and 
increasing the stability of the atherosclerotic plaque 
IMPORTANCE OF QUALITY OF LIFE STUDIES 
   The growing recognition of the importance of assessing the effects of epilepsy on 
psychosocial functioning has led to the need to define and quantify quality of life in affected 
individuals. Quality of life (QOL) is a subjective issue and one that is determined from the 
patient’s point of view depending on clinical, psychosocial and demographic variables.(7) 
    Measuring the outcome of treatment of epilepsy traditionally has been in the realm of 
the health care provider, who assesses results of treatment by using seizure frequency and 
severity, adverse effects, and antiepileptic drug (AED)-level parameters. Patient perceptions 
of outcome often include additional parameters that encompass the effects of epilepsy on 
daily activities and functions(8) . This expanded scope of impact was defined by the World 
Health Organization (WHO) as health-related quality of life: “a state of complete physical, 
mental, and social well-being and not merely the absence of disease or infirmity”. 
   Surveys of patients and physicians have confirmed the usefulness of these screening 
questions in improving communication and raising issues between patients and providers . To 
improve the specificity of information, generic questionnaires need to be tailored for special 
populations (e.g., persons with epilepsy) with supplementary items pertinent to problems 
typically reported by that population(9). 
QOLIE-10 QUESTIONNAIRE(12) 
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     It is a brief questionnaire to screen aspects of health-related quality of life for persons 
with epilepsy. The QOLIE- 10 is a simple screening questionnaire that can be completed 
easily and quickly by patients. The 10 items fall into three distinct topics as (a) medication 
effects, (b) mental health, and (c) role functioning and seizure worry, all of which pertain to 
aspects of daily living for persons with epilepsy. 
      The QOLIE-I0 provides individual patients with an opportunity to denote epilepsy-
related problems and express their concerns to health-care providers. Unlike diagnostic or 
laboratory individual functions in the real world (e.g., work and social opportunities, 
transportation, independent living, worry about seizures). 
     Screening data have several clinical applications for quality of life: (a) alert physician and 
clinic staff to common patient concerns, (b) inform patients of problems common for this 
disorder, and (c) facilitate interaction between and decision making by patient and 
physician.(13)  
 
   The QOLIE-10 screening questionnaire includes 11 questions. Three questions have 
opposite response sets, requiring reverse-scoring. The scoring should be calculated so that all 
positive responses are lower numbers and all negative responses are higher numbers. The 
responses obtained are subjected to the scoring tool. The Mean Score is the sum of scores for 
all questions divided by the number of items answered. The Mean Score is multiplied by the 
response for Item 11 to create the final “weighted” score(14).  If one item is missing, the score 
may be imputed based on the 9 responses. If more than one item is missing, the instrument is 
not valid.  Higher scores represent better quality of life (15). 
   
STATIN USE IN PWE 
      Antiepileptic drugs, including carbamazpine, phenytoin, and phenobarbital, are among 
the most commonly-prescribed medications for seizres throughout the world. Evidence 
indicates that these agents, probably via their widespread impact upon the cytochrome P450 
system, engender a host of metabolic derangements, including elevations of serum lipids and 
other serologic markers of vascular risk.(16) These effects would be expected to materially 
increase the risk of vascular disease, based upon estimation from population studies in the 
cardiovascular literature, and additional surrogate markers.(17) 
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        The enzyme-inducing AEDs phenytoin (PHT), phenobarbital (PB), carbamazepine 
(CBZ), and primidone (PRM) increase the activity of the hepatic cytochrome P450 system, 
which is involved in synthesis of serum cholesterol. Animal data show that a particular 
enzyme, CYP51A1, catalyzes the conversion of lanosterol into cholesterol intermediates 
.When these intermediate build up through inhibition of the enzyme, they in turn inhibit the 
rate-limiting step of cholesterol synthesis, 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase(18), and slow the synthesis of cholesterol. It follows that induction of CYP51A1 
should therefore increase cholesterol production through metabolism of these intermediates 
and reduced feedback inhibiton(19).  
      While the pathway has not been explicitly studied in humans to our knowledge, this 
mechanism engenders some predictions regarding the effects of certain AEDs in patients. For 
example, an enzyme-inducing AED such as CBZ should increase serum cholesterol. On the 
other hand, valproic acid (VPA), an enzyme-inhibiting medication, should decrease 
metabolism of intermediates and increase feedback inhibition, thereby decreasing production 
of cholesterol. 
      The discovery of a class of drugs, the statins, which selectively inhibit 3-hydroxy-3-
methylglutaryl-CoA reductase (HMG-CoA reductase) was a significant advance in the 
treatment of dyslipidaemia. Their primary site of action is the inhibition of HMG-CoA 
reductase in the liver and the subsequent inhibition of the formation of mevalonic acid, the 
rate-limiting step in the biosynthesis of cholesterol. This results in a reduction in intracellular 
levels of cholesterol, an increase in expression of hepatic LDL receptor, and enhanced 
receptor-mediated catabolism and clearance of LDL-C from serum. 
     The statins are a heterogeneous group metabolised by different CYP450 isoenzymes. 
Simvastatin, atorvastatin and lovastatin are metabolised by CYP3A4, fluvastatin is 
metabolised by CYP 2C9, and pravastatin and rosuvastatin are eliminated by other metabolic 
routes and less subject to interactions with CYP450 isoenzymes than other members of the 
family. Nevertheless, caution is still required as a 5- to 23-fold increase in pravastatin 
bioavailability has been reported with ciclosporin. Simvastatin and atorvastatin do not alter 
the activity of CYP3A4 themselves, but their serum levels are increased by known inhibitors 
of CYP3A4. 
     In patients receiving a statin, a once-daily regimen involving an evening dose is often 
preferred. Several of the statins (fluvastatin, pravastatin, simvastatin) are claimed to be more 
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effective when given as a single dose in the evening compared to a similar dose administered 
in the morning. This has been attributed to the fact that cholesterol biosynthesis reaches peak 
activity at night. However, atorvastatin and rosuvastatin may be taken in the morning or 
evening with similar efficacy. 
 
ASSESSMENT OF CARDIOVASCULAR DISEASE RISK 
     The Framingham risk score (FRS) is a simplified and common tool for the assessment of 
risk level of CAD over 10 years . The FRS considers six coronary risk factors, including age, 
gender, total cholesterol (TC), high density lipoprotein cholesterol (HDL), smoking habits, 
and systolic blood pressure. FRS is the most applicable method for predicting the person’s 
chance of developing cardiovascular disease (CVD) in long term(20). 
     FRS was used to investigate the risk of cardiovascular disease. FRS scores were calculated 
based on the six coronary risk factors including age, gender, TC, HDL-cholesterol, systolic 
blood pressure, and smoking habits. The cutoffs for calculating FRS were as follows: 
TC < 160, 160–199, 200–239, 240–279, and ≥ 280 mg/dL; for systolic blood pressure: < 120, 
120–129, 130–139, 140–159, and ≥ 160 mmHg; and for HDL-C: < 40, 40–49, 50–59, and ≥ 
60 mg/dL . Ten-year risk in percentage was calculated by total points (1 point 6%, 2 points 
8%, 3 points 10%, 4 points 12%, 5 points 16%, 6 points 20%, 7 points 25%, 10 points or 
more > 30%). Absolute CVD risk percentage over 10 years was classified as low risk (< 
10%), intermediate risk (10–20%), and high risk (> 20%)(21). 
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ABSTRACT 
       The work entitled ” A prospective, observational study on prevalence of 
cardiovascular risk factors and  statin use in patients with epilepsy and  assessment of quality 
of life” was conducted in the department of neurology of a 1000 bedded multispecialty 
hospital .The study protocol was prepared and submitted to the ethical committee of the 
hospital and official approval was obtained to carry out the study after ensuring the scope of 
the study in the department of neurology of the study hospital. After receiving the official 
approval, the study was conducted for a period for a period of nine months from December 
2017 to August 2018. A total of 130 cases with epilepsy were collected. Prior consents from 
the patients were taken after explaining them the need of the study. 
      The analysis of the study conducted for eight months revealed that there were 
79(61%) male patients and 51 (39%) female patients who fit into the inclusion criteria. The 
age categorization of the study population indicated that maximum number of patients are 
between the age group of 51-65 (36%) followed by age group of 35-50 (32%). Hypertension 
(28%) and Diabetes(18%) were the major comorbid conditions among epilepsy patients. 
Patients with smoking (11%) and drinking (7%) habits were also documented during the 
study. No patients with previous coronary artery disease were included in the study. The 
majority of the patients were known cases of epilepsy for more than a year (83%). The 
majority of the patients were diagnosed with generalised tonic clonic seizures (37.5%), 
followed by partial seizures with secondary generalisation(31%). 
      To find out any rationality in therapy, an attempt was made to know about  the 
concurrent drugs prescribed. The results revealed that proton pump inhibitors (89%), 
antibiotics (51%), lipid lowering agents (52%) and antiemetics (58%) were the major 
category of drugs prescribed. Antidiabetic drugs (16%) and antihypertensive drugs (26%) dr 
were major category of drugs prescribed since high prevalence of hypertension and diabetes 
was observed as comorbidity in the study population. Levetiracetam (84%), was the 
maximum prescribed antiepileptic drug in the study department, followed by fosphenytoin 
(32%),lacosamide (24%) and clobazam (20%).The drug interaction between atorvastatin and 
pantoprazole was the mostly recorded drug interaction,which was observed in 15 patients 
with moderate severity. Among the study population 85(65%) patients were receiving 
polypharmacy and 45(35%) patients were receiving monotherapy. A total of 68(52%) of 
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patients were receiving lipid lowering drugs, in which 51(39%) patients were having lipid 
profile data. 
     The health related quality of life of epilepsy patients were assessed by direct 
interviewing the patients with QOLIE-10-P questionnaire. The QOLIE-I0-P questionnaire 
provided individual patients with an opportunity to denote epilepsy-related problems and 
express their concerns to health-care providers. The brevity of this screening tool has the 
potential of saving  time without sacrificing the quality of information collected or interfering 
with the relationship between the patient and the researcher. The QOLIE- 10-P questionnaire 
is a simple screening questionnaire that can be completed easily and quickly by patients. The 
10 items fall into three distinct topics as (a) medication effects, (b) mental health, and (c) role 
functioning and seizure worry, all of which pertain to aspects of daily living for persons with 
epilepsy. The 11th question enables the patient to express his feelings on the burden of 
epilepsy on his/her normal life. 
     The scoring tool for QOLIE-10-P questionnaire was obtained from the QOLIE 
development group and used. The mean score of the first 10 questions were calculated and its 
mean was multiplied with the score obtained for the 11th question to produce the weighted 
final score. 
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LITERATURE REVIEW 
Martin J. Brodie et al (2018) published The International League against Epilepsy 
(ILAE) published in the April 2017 edition of Epilepsia three companion articles on the 
classification of seizures and the epilepsies. These represent a long-awaited update on the 
original 1981 and 1989 publications and provide a modern descriptive template. The new 
classification presents three levels of terminology, involving seizure types, epilepsy types, 
and syndromes. In this fourth paper, we present an interpretation of thesenewconcepts for 
people with epilepsy and those who care for them, as well as for young medical doctors not 
specialized in epilepsy and nurses. Our goal in writing this paper is to ensure that everyone is 
speaking and understanding the same language, which is fundamental to the optimal 
management of people with epilepsy. 
Prakruti Patel et al (2017) undertaken a study to   measure efficacy and tolerability 
of antiepileptic drugs in patients of epilepsy with a particular reference to the impact on 
quality of life (QOL). The efficacy of the drug therapy was calculated by counting the 
number of seizure per month using seizure diary. QOL was measured using Quality of Life in 
Epilepsy-31-P questionnaire .Antiepileptic drugs are efficacious in treating and improving the 
quality of life of patients suffering from epilepsy. 
Dong Wook Kim  et al (2017) performed  a study to assess the effects of lifestyle 
modification and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor 
(statin) therapy on the increased circulatory markers for vascular risk in patients with 
epilepsy. The circulatory markers of vascular risk were measured twice before and after a 3-
month intervention. There were no reports of serious adverse events or seizure aggravation 
related to the statin treatment. Our findings suggest that lifestyle education is necessary in 
patients with epilepsy with increased vascular risk and that treatment with statin would be a 
well-tolerated and effective option for these patients. 
Leila Jahangiry et al (2017) conducted a study evaluating the predictive value of 
Framingham risk score (FRS) for cardiovascular disease (CVD) risk assessment in patients 
with metabolic syndrome in Iran. Because of the emerging high prevalence of CVD among 
Iranian population, it is important to predict its risk among populations with potential 
predictive tools. Therefore, the aim of the current study is to evaluate the FRS and its 
determinants in patients with metabolic syndrome. In the current study, significant 
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associations between components of metabolic syndrome and different FRS categorization 
among patients with metabolic syndrome were identified. High SBP and FSG were 
associated with meaningfully increased risk of CVD compared with other parameters. 
Halley B. Alexander et al(2017) conducted a study to evaluate the effects of AED 
polypharmacy on QOL while  accounting  for seizure status and other potential covariates. 
The  purpose of the study was to determine the association of polypharmacy with QOL. Two 
hundred seven patients with epilepsy were surveyed on characteristics within the last 4 
weeks: QOL Quality of Life in Epilepsy-Patient-Weighted (QOLIE-10-P) and seizure status 
(seizure-free or not), demographics, epilepsy characteristics, insomnia, sleepiness, mood, 
sleep–wake timing, healthcare use, and employment. Those on polypharmacy (antiepileptic 
drug (AED) N 1) were compared with controls (AED = 1) with univariate comparisons and 
subsequent multivariate regression. Polypharmacy was associated with worse QOL  even 
after controlling for seizure status. Covariates offered no improvement to the model.  
Polypharmacy was associated with worse QOL in patients with epilepsy despite seizure 
control. Further investigation into specific etiology of polypharmacy's influence on QOL is 
warranted in order to develop paradigms for optimal treatment. 
RK Surekha et al (2017) conducted a study to determine the level of health related 
quality of life of  patients with epilepsy in a teaching hospital.The study revealed that patients 
who were on a single drug(monotherapy) had a much better QOL than the patients on more 
than one drug(polytherapy). 
Green B et al(2017) examined to what extent attachment style and relationship 
quality with their main informal carer impact on levels of HRQoL, depression, and anxiety in 
patients with PNES versus those with epilepsy. Patients with PNES reported higher levels of 
anxiety and depression and lower HRQoL, than those with epilepsy. PNES: No significant 
correlations were found with HRQoL but depression correlated positively with attachment 
avoidance, attachment anxiety, and relationship conflict. Anxiety correlated positively with 
attachment avoidance, attachment anxiety, and relationship conflict, and negatively with 
relationship depth and support Levels of anxiety and depression were higher in patients with 
PNES than those with epilepsy. Interpersonal problems were much more closely associated 
with anxiety and depression in patients with PNES than those with epilepsy. The findings 
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support the use of therapeutic interventions for PNES focusing on attachment and 
relationship issues. 
Vivanco-Hidalgo et al (2016) conducted a study to compare the prevalence of 
cardiovascular risk factors (CVRFs), cardiovascular risk and statin use in people with 
epilepsy (PWE) and the general population. The CVRFs and cardiovascular risk score were 
compared between 815 PWE from an outpatient register and 5336 participants from a general 
population cohort.  Patients taking enzyme-inducing antiepileptic drugs (EIAEDs) had more 
dyslipidemia than the general population (41.6% vs. 34.6%) but similar cardiovascular risk. 
Independently of risk or CVRFs, PWE had 60% more probability of receiving statins than the 
general population. People with epilepsy had more dyslipidemia, related to EIAEDs, and 
lower cardiovascular risk but still took more statins than the general population. 
 Jerzy P. Szaflarski et al (2016) examined the provision of care to older adults with 
epilepsy and compliance with the “Quality Indicator for Epilepsy Treatment 15” (QUIET-15) 
measure. Overall, aminority ofMedicare beneficiaries experienced seizure recurrence that 
resulted in an ER visit. However, only half of themreceived treatment concordantwith 
QUIET-15. Though racial differences were observed in occurrence of seizures, none were 
noted in the provision of care. 
  Altaf Saadi et al (2016) conducted a study to assess the quality of life in epilepsy 
(QOLIE) among adults in the lower middle-income country of Bhutan and assess the 
potential demographic and clinical associations with better QOLIE. People with clinically 
diagnosed epilepsy were prospectively enrolled at the Jigme Dorji Wangchuck National 
Referral Hospital in Thimphu (2014–2015). Regression models were constructed to assess the 
potential impact of age, sex, residence in the capital city, wealth quintile, educational 
attainment, seizure in the prior year, seizures with loss of consciousness, self-reported stigma 
score, and need for multiple antiepileptic drugs. There are potentially modifiable associations 
with low QOLIE. Addressing the educational level and self-perceived stigma of PWE may 
have an especial impact. The low QOLIE in Bhutan may reflect cultural approaches to 
epilepsy, health services, or other factors including those outside of the health sector. 
      A Staniszewska et al (2015) conducted a study to identify the demographic and 
socioeconomic factors that are associated with a poor quality of life in patients with epilepsy. 
The analysis of variance did not show any significant relation between quality of life and all 
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subscales QOLIE-31 and sex or driving license. The cognition domain showed the worst 
scores. 
   Scott Mintzer et al (2014) undertaken a study to suggest that EIAEDs produce 
elevation of serum lipids, which could require additional treatment. We assessed the current 
use of EIAED in monotherapy for epilepsy in the U.S., as well as the correlation between use 
of EIAEDs and subsequent new prescriptions for HMG-CoA reductase inhibitors (“statins”) 
for hyperlipidemia. EIAED prescription for epilepsy appears to increase with increasing age 
in the U.S. despite the absence of a cogent rationale for this practice, suggesting a failure to 
appreciate the complications of EIAED therapy among U.S. physicians. Statins were more 
often started in those newly-prescribed EIAEDs than to those given non-inducing AEDs. 
These preliminary data provides further evidence suggesting that EIAEDs elevate lipids in a 
clinically meaningful manner. 
  Niki Katsiki et al(2014)   studied the association of epilepsy  with increased 
cardiovascular disease (CVD) morbidity and mortality. The exact causes of this link are not 
clearly defined. The role of antiepileptic drugs (AEDs) in influencing CVD risk in patients 
with epilepsy remains controversial. A link between epilepsy, AEDs and cardiac arrhythmias 
has been proposed and may be responsible for sudden unexpected death in epilepsy. We 
searched MEDLINE up to December 1, 2013 for relevant publications using combinations of 
keywords. We also examined the reference list of articles identified by this search and 
selected those we judged relevant. These were included in this narrative review. AEDs may 
exert both beneficial and adverse cardiovascular effects. This narrative review considers the 
influence of AEDs on some predictors of vascular. Certain AEDs can also have pro-
arrhythmic properties. AEDs may exert different effects on various established and emerging 
predictors of vascular risk. Furthermore, pharmacokinetic interactions between AEDs and 
drugs used to reduce vascular risk (e.g. statins) need to be better documented. 
 NURULUMI AHMAD et al (2013) carried out a study to assess the adherence 
intention towards pharmacotherapy and its impact on quality of life in epilepsy patients. This 
study demonstrates that adherence intention has a significant impact on patient quality of life. 
Therefore, adherence intention should be monitored to provide appropriate support in 
improving quality of life in epilepsy patients. 
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    Ane Gedde-Dahl et al (2012) performed a study was to compare statin prescription 
in patients receiving EIAEDs versus non-enzyme-inducing antiepileptic drugs (NEIAEDs), 
before and after introduction of prescribing restrictions for statins in Norway. The Norwegian 
Prescription Database was used to extract data on patients using antiepileptic drugs and 
statins during 2004 and 2008. Statin type and dose used were compared between patients 
treated with at least one EIAED (i.e., carbamazepine, phenobarbital, phenytoin, primidone) 
and those receiving NEIAEDs only (i.e., all other antiepileptic drugs). The present study 
shows that the interaction risk between CYP3A4-metabolized statins and EIAEDs is largely 
overlooked in Norwegian clinical practice. To avoid therapeutic failure of statin treatment in 
patients using AEDs, implementation of strategies for systematic management of drug 
interactions is warranted. 
 Romy Mahrer-Imhof et al (2012) conducted a study to investigate factors that 
influence QoL in hospitalized adult patients with epilepsy and their relatives. Epilepsy is not 
only a neurological disorder but may also have negative psychosocial consequences on 
people with epilepsy (PWE) and their relatives. Epilepsy has a major impact on quality of life 
(QoL) in PWE and family members. However, less is known about the impact of family 
support and family functioning on quality of life for PWE and family members and their 
interaction. Therefore, the study aimed to investigate factors that influence QoL in 
hospitalized adult patients with epilepsy and their relatives.  The patients’ QoL, however, 
depended significantly on the QoL of the family members. Interventions should address both 
PWE and family members and focus on the self-care improvement of PWE and the well-
being and coping of family members. A patient-centred approach needs to include both the 
PWE and the relatives and address family support in order to alleviate stress in the patients 
and relatives alike. 
 Devender Bhalla et al( 2012) carried out a study to Identify epilepsy-associated 
factors and calculate measures of impact, stigma, quality of life (QOL), knowledge attitude- 
practice (KAP) and treatment gap in Prey Veng, Cambodia. QOL scores in our population 
were not better than resource-rich populations which might be due to better healthcare 
possibilities or with respect to different sociocultural environments 
Christoph Helmstaedter et al (2011) conducted a prospective, multicenter, non-
interventional surveillance study (ZADE study) which explored seizure outcome and 
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tolerability of adjunctive treatment with zonisamide (ZNS) in a non-selected sample of 
patients with partial-onset seizures in everyday clinical practice. Changes in quality of life 
(QOL) and health status were also recorded. Clinical status was assessed before and 4 months 
after introduction of ZNS. In conclusion, adjunctive treatment with ZNS seems to be 
efficacious and well tolerated. QOL improvement was predicted by baseline score, seizure 
outcome, and overall drug load, and is thus more likely a result of enhanced seizure control, 
rather than an intrinsic psychotropic effect of zonisamide. 
Emilio Perucca et al(2005) carried out a study to understand the clinically relevant 
drug interactions with antiepileptic drugs. Some patients with difficult-to-treat epilepsy 
benefit from combination therapy with two or more antiepileptic drugs (AEDs). Additionally, 
virtually all epilepsy patients will receive, at some time in their lives, other medications for 
the management of associated conditions. In these situations, clinically important drug 
interactions may occur. Interactions involving AEDs have not been well characterized, but 
their understanding is important for a more rational approach to combination therapy. In 
particular, neurotoxic effects appear to be more likely with coprescription of AEDs sharing 
the same primary mechanism of  action. 
Joyce A Cramer et al (1996) conducted am evaluation of a brief questionnaire to 
screen aspects of health-related quality of life for persons with epilepsy. A study of 304 
adults with epilepsy was undertaken at 25 seizure clinics in the United States. It was used for 
derivation of a brief screening tool from a longer instrument (QOLIE-89). The 10-item 
questionnaire (QOLIE-10) covers general and epilepsy-specific domains, grouped into three 
factors: Epilepsy Effects (memory, physical effects, and mental effects of medication), 
Mental Health (energy, depression, overall quality of life), and Role Functioning (seizure 
worry, work, driving, social limits). Scale scores were significantly different among seizure 
groups (p =0.003). The QOLIE-10 can be completed by a patient in several minutes and 
reviewed rapidly by the physician. This screening tool could provide potentially useful 
information for initial assessment or follow-up of problem areas that are not commonly 
evaluated during routine clinical visits with patients with epilepsy. 
. 
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SCOPE  OF THE STUDY 
 Epilepsy is one of the oldest conditions known to mankind and still one among the 
most common neurological conditions affecting individuals of all ages. According to ILAE 
Guidelines, a person with active epilepsy is one who has had at least one epileptic seizure in 
the previous five years, regardless of anti-epileptic drug treatment.  Epilepsy in remission 
indicates that the patient has been seizure free for five or more years with or without 
treatment. All medical conditions that are chronic impact to a greater or lesser degree on the 
life quality of those affected by them. Epilepsy is a chronic condition characterized by 
clinical uncertainty. Epilepsy is an example of a medical diagnosis that is retained even when 
signs and symptoms are well controlled and all laboratory tests are normal. 
QOL is a subjective issue and one that is determined from the patient’s point of view 
depending on demographic, clinical and socioeconomic factors. Health-related quality of life 
(HRQOL) has been defined by WHO as “a state of complete physical, mental, and social 
well-being and not merely the absence of disease or infirmity”. The QOLIE-10-P provides 
individual patients with an opportunity to denote epilepsy-related problems and express their 
concerns to healthcare providers. Thus, although it was designed as a screening tool, it can 
still be scored and used in research. 
The overall quality of life is worse in patients with epilepsy than in the general 
population. It was comparable or worse in patients with epilepsy than that in patients with 
other chronic conditions; and it was similar to that of healthy persons when patients with 
epilepsy were well-controlled. QOL is influenced by biological factors as well as cultural, 
social and religious beliefs and values. QOL of patients with epilepsy depended upon 
effectiveness of anti-epileptic therapy and disease duration. Due to the special nature and 
course of the disease, chronic pharmacotherapy and numerous socioeconomic factors 
influence the quality of patients with epilepsy. The duration of epilepsy may play an 
important role in QOL, therefore we analysed the relationship between quality of life and 
duration of disease.  
  A high frequency seizure rate usually limits the amount of daily activity in patients’ 
everyday lives. This fact leads to impairment of physical activity and social functioning, as 
well as to psychological problems. Depression and anxiety are common psychiatric 
symptoms in patients with epilepsy, exerting a profound negative effect on their health-
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related quality of life. The adverse effects remain the leading cause of failures in treatment 
and the major determinant of the impaired health related quality of life in people with 
epilepsy. 
The brevity of this screening tool has the potential of saving physician time without 
sacrificing the quality of information collected or interfering with the physician-patient 
relationship. Patients can complete the questionnaire while waiting to be seen, complete it at 
home and bring it to the next visit, or return it by mail for later use.The QOLIE-I0 provides 
individual patients with an opportunity to denote epilepsy-related problems and express their 
concerns to health-care providers. Unlike diagnostic or laboratory tests that report whether a 
patient’s results are within the “normal” range, quality-of-life instruments indicate how an 
individual functions in the real world (e.g., work and social opportunities, transportation, 
independent living, worry about seizures). 
Asking the patient to complete the QOLIE-10-P before seeing the physician brings 
fresh information to the clinical interview in a uniform style that could enhance the patient’s 
ability to focus on issues pertinent to epilepsy while economizing on the amount of time the 
physician needs to cover the range of health-related quality-of-life topics. Antiepileptic drugs 
are able to alleviate the symptoms but may produce adverse reactions which may also affect 
the quality of life in epilepsy patients. Therefore, measurement of quality of life is considered 
vital for the care of epileptic patients. Antiepileptic drugs are efficacious in treating and 
improving the quality of life of patients suffering from epilepsy. Hence, the choice of therapy 
depends on the cost of therapy as well as availability and tolerability of the drug in public 
health care setup. It is recommended that besides providing an optimum drug treatment that 
relieves the current symptoms of the disease, quality of life should also be considered as a 
prognostic tool and attempts should also be made to provide a psycho-social support to obtain 
a significant improvement in quality of life. 
Enzyme-inducing antiepileptic drugs (EIAEDs), including carbamazpine, phenytoin, 
and phenobarbital, are among the most commonly-prescribed medications for seizures 
throughout the world. Mounting evidence indicates that these agents, probably via their 
widespread impact upon the cytochrome P450 system, engender a host of metabolic 
derangements, including elevations of serum lipids and other serologic markers of vascular 
risk. These effects would be expected to materially increase the risk of vascular disease, 
based upon estimation from population studies in the cardiovascular literature, and additional 
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surrogate markers. Ideally, a direct assessment could be made to determine whether exposure 
to these drugs is associated with elevated incidence of vascular events. But the 
hyperlipidemia caused by EIAEDs might easily and incidentally be picked up by primary 
care physicians performing routine health screening. If the lipid elevation is clinically 
significant, then treatment with an lipid-lowering agent may be initiated, often with no 
knowledge that the anticonvulsant is contributing to the problem. This may add to the costs 
and potential complications of care for patients. It is difficult to assess vascular risk in 
patients with epilepsy because the excess risk has not been definitively quantified or 
recognized by the guidelines of learned societies. We suggest the usual risk assessment with 
consideration that an additional risk may exist in patients with epilepsy. The choice of AEDs 
may also need to be considered in patients with metabolic or other vascular risk factors. 
The Framingham risk score (FRS) is a simplified and common tool for the assessment 
of risk level of CAD over 10 years. The FRS considers six coronary risk factors, including 
age, gender, total cholesterol (TC), high density lipoprotein cholesterol (HDL), smoking 
habits, and systolic blood pressure. FRS is the most applicable method for predicting the 
person’s chance of developing cardiovascular disease (CVD) in long term. Because this risk 
score gives an indication of the likely benefits ofprevention, it can be useful for both the 
patients and clinicians deciding whether lifestyle modification and preventive medical 
treatment and for patients education by identifying men and women at increased risk for 
future cardiovascular events. 
Evidence of a link between epilepsy and increased CVD morbidity and mortality, has 
been available for several decades. Despite that, there is still a substantial need for definitive 
recommendations to optimize prevention for these patients. 
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OBJECTIVES 
 To study the prevalence of cardiovascular risk and  use of lipid lowering drugs like 
statins in patients with epilepsy. 
 To measure the impact of antiepileptic drugs on quality of life of patients with 
epilepsy. 
 To evaluate the effects of AED polypharmacy on quality of life. 
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PLAN OF THE STUDY 
Phase 1 
 To obtain consent from the hospital authorities to carry out the study at the intended 
department. 
Phase 2 
 To document all the epilepsy cases which satisfy the inclusion criteria and cases 
which are admitted in the Department of Neurology of multi-specialty hospital. 
Phase 3 
 To analyse the statins prescriptions and evaluate the 10 year cardiovascular risk of 
patients prescribed with statins by using Framingham risk score. 
 To evaluate the health related quality of life of patients with epilepsy and understand 
the effect of AED polypharmacy on QOL. 
Phase 4 
 To perform the statistical analysis on the collected data to ensure the reliability and 
acceptability of the data. 
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METHODOLOGY 
The study was  carried out in a 1000  bedded multispeciality tertiary care teaching 
hospital in Coimbatore. The hospital is unique and well known for its service to the people 
who come from various part of the country. The institution excels in diverse specialities like 
General medicine, General surgery, Obstetrics, Gynecology, Paediatrics and Neonatology, 
Orthopedics, Psychiatry, Neurology, Radiology, Cardiology, Nephrology, E.N.T, 
Opthalmology, Oncology, Dentistry, Plastic surgery, and  department of physical 
rehabilitation. The hospital has well- staffed Pharmacy and a Drug Information Centre. The 
hospital is well equiped with modern diagnostic facilities like CT scan, MRI, ECG, tread 
mill, colour doppler,etc. The hospital also have twelve well equiped Hi-tech operation 
theatres , Intensive Care Unit, Intensive cardiac unit, Intensive pulmonary care unit, NICU, 
Catheterisation laboratory performing diagnostic cardiac catheterisation, balloon 
valvuloplasty, coronary stenting, kidney transplantation unit with hemodialysis machines, 
assisted reproductive technology centre, 24 hour micrbiological and pathological services, 
blood bank, round the clock casuality and pharmacy services . 
DEPARTMENT SELECTED FOR THE STUDY 
   The study was conducted in the department of neurology.  The reason for the 
selection of the department of neurology was that the pilot study revealed more scope for the 
study in the department of neurology as the prevalence of epilepsy cases are more. When 
prescribing, the knowledge on the different types of co-morbidities prevailing and 
accordingly changes required in treating various stroke study cases in the hospital will help 
the healthcare professionals to select the appropriate drugs to ensure rational therapy. The 
study was conducted with expert guidance of the clinical pharmacy professionals and senior 
neurologist of the study hospital. Prior permission was also obtained from the chief of the 
concerned department. 
CONSENT FROM HOSPITAL AUTHORITIES  
  A protocol of the study which includes the objectives, methodology an probable 
outcome was prepared and submitted to the Institutional Ethical Committee. The approval 
from the committee was procured and the same is attached to reference in the Annexure 1. 
The study was conducted with the expert guidance of senior and junior physicians of the 
study departments. The authors were allowed to utilize the hospital facilities to make a follow 
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up of the cases, in the selected departments. All the health care professionals of the study site 
were well informed through Dean’s official circular. 
LITERATURE SURVEY 
  An extensive literature survey was carried out regaeding the study entitled “A 
prospective, observational study on prevalence of cardiovascular risk factors and  
statin use in patients with epilepsy and assessment of quality of life”. The literatures were 
collected from various journals including: 
 European journal of neurology 
 British journal of clinical pharmacology 
 Journal of basic and clinical pharmacy 
 American journal of family  medicine 
 Journal of clinical neurology 
 International league against epilepsy 
 Seizure journal 
 Neurology Asia 
 Research in neurology 
 Journal of neuroscience in rural practice 
 Neurology India  
 Annals of Indian academy of neurology 
 
PATIENT SELECTION 
Inclusion criteria 
Patients of either sex admitted in the neurology department during the study period 
and are receiving drugs for the management of epilepsy with no history of previous 
cardiovascular events. 
 Exclusion criteria 
Patients who were not diagnosed with epilepsy and those with insufficient data in 
their records. Pregnant and lactating women were excluded. 
 
 
 
Methodology 
 
A prospective, observational study on prevalence of cardiovascular risk factors and  
statin use in patients with epilepsy and assessment of quality of life   30 
 
STUDY DESIGN 
A prospective cross sectional study was carried out in the neurology department to 
find the prevalence of cardiovascular risk and quality of life in patients with epilepsy. 
Patients who have been diagnosed with epilepsy were selected as per inclusion criteria. A 
standardised patient profile form to document the data was designed to collect demographic 
details of the study population. 
 
DATA ENTRY FORM : 
  
A specially designed data entry format was prepared and used to record the patients 
details. Data entry format has the provision to record patient details such as name, age,sex, 
height, weight, IP.Number, date of  admission and discharge, reason for admission, patient 
medical and medical history, vital signs, laboratory investigations, comorbidities, diagnosis, 
drug chart, drug interaction monitoring chart. The same is given in the Annexure No.4 for 
reference. 
 
QOLIE -10-P questionnaire 
    It  is a brief questionnaire to screen aspects of health-related quality of life for persons with 
epilepsy. The QOLIE- 10 is a simple screening questionnaire that can be completed easily 
and quickly by patients. The 10 items fall into three distinct topics as (a) medication effects, 
(b) mental health, and (c) role functioning and seizure worry, all of which pertain to aspects 
of daily living for persons with epilepsy. The QOLIE-I0 provides individual patients with an 
opportunity to denote epilepsy-related problems and express their concerns to health-care 
providers. Unlike diagnostic or laboratory individual functions in the real world (e.g., work 
and social opportunities, transportation, independent living, worry about seizures) . Screening 
data have several clinical applications for quality of life: (a) alert physician and clinic staff to 
common patient concerns, (b) inform patients of problems common for this disorder, and (c) 
facilitate interaction between and decision making by patient and physician . The 10 simple 
questions in the QOLIE-10 may serve as a screen for problems. A higher quality of life is 
reflected by a lower score. Higher the QOL score greater is the impairment of QOL. 
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FRAMINGHAM RISK SCORE 
Framingham risk score was used to know the cardiovascular risk of patients in the study  
population who were prescribed with lipid lowering drugs. Framingham risk score is a  
gender specific algorithm used to estimate the 10 year cardiovascular risk of an individual. 
The Framingham risk score was developed based on the data btained based on the 
Framingham heart study, to estimate the 10-year riskof developing coronary heart disease. 
FRS is the most applicable method for predicting the person’s chance of developing 
cardiovascular disease (CVD) in long term. 
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RESULTS AND DISCUSSION 
        The work entitled “A prospective, observational study on prevalence of 
cardiovascular risk factors and statin use in patients with epilepsy and assessment of 
quality of life” was conducted in the department of neurology of a 1000 bedded 
multispecialty hospital .The study protocol was prepared and submitted to the  of the hospital 
and official approval was obtained to carry out the study after ensuring the scope of ethical 
committee the study in the department of neurology of the study hospital. After receiving the 
official approval, the study was conducted for a period for a period of  eight months from 
December 2017 to July 2018 . A total of 130 cases with epilepsy were collected. 
       The analysis of the study conducted for eight months revealed that there were 
79(61%) male patients and 51 (39%) female patients who fit into the inclusion criteria. The 
age categorization  of the study population indicated that maximum number of patients are 
between the age group of 51-65 (36%) followed by age group of 35-50 (32%). Hypertension 
(28%) and Diabetes(18%) were the major comorbid conditions among epilepsy patients. 
Patients with smoking (11%) and drinking (7%) habits were also documented during the 
study. No patients with previous cardiovascular events were included in the study. 
 The majority of the patients were diagnosed with generalised tonic clonic 
seizures(37.5%), followed by partial seizures with secondary generalisation(31%). To find 
out any rationality in therapy, an attempt was made to know about the concurrent drugs 
prescribed. The results revealed that proton pump inhibitors (89%), antibiotics (51%), lipid 
lowering agents (52%) and antiemetics (58%) were the major category of drugs prescribed. 
Antidiabetic drugs (16%) and antihypertensive drugs (26%) dr were major category of drugs 
prescribed since high prevalence of hypertension and diabetes was observed as comorbidity 
in the study population. Levetiracetam (84%),was the maximum prescribed antiepileptic drug 
in the study department, followed by fosphenytoin (32%),lacosamide (24%) and clobazam 
(20%).The drug interaction between atorvastatin and pantoprazole was the mostly recorded 
drug interaction,which was observed in 15 patients with moderate severity.  
Among the study population 85(65%) patients were receiving polypharmacy and 
45(35%) patients were receiving monotherapy. A total of 68(52%) of patients were receiving 
lipid lowering drugs, in which 51(39%) patients were having lipid profile data, 
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The health related quality of life of epilepsy patients were assessed with direct 
interviewing of the patients with QOLIE-10-P questionnaire. The QOLIE-I0-P provided 
individual patients with an opportunity to denote epilepsy-related problems and express their 
concerns to health-care providers. The brevity of this screening tool has the potential of 
saving  time without sacrificing the quality of information collected or interfering with the 
relationship between the patient and the researcher. The QOLIE- 10-P is a simple screening 
questionnaire that can be completed easily and quickly by patients. The 10 items fall into 
three distinct topics as (a) medication effects, (b) mental health, and (c) role functioning and 
seizure worry, all of which pertain to aspects of daily living for persons with epilepsy. The 
11th question enables the patient to express his feelings on the burden of epilepsy on his/her 
normal life. 
     The scoring tool for QOLIE-10-P was obtained from the QOLIE development group 
and used. The mean score of the first 10 questions were calculated and its mean was 
multiplied with the score obtained for the 11th question to produce the weighted final score. 
    The cardiovascular risk and statin use were analyzed for the study population. 
Framingham risk score was used to analyse the CVD risk of the patients. FRS is the most 
applicable method for predicting the person’s chance of developing cardiovascular disease 
(CVD) in long term. The FRS considers six coronary risk factors, including age, gender, total 
cholesterol (TC), high density lipoprotein cholesterol (HDL), smoking habits, and systolic 
blood pressure. The results obtained were subjected for statistical analysis. 
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GENDER DISTRIBUTION 
The total number of patients in the study were 130 of which 79(61%) were males and 
51(39%) were females.The study results showed that mostly males were affected with 
epilepsy. 
           Sex  No. of epilepsy patients Percentage (%) 
          Male                79          61 
         Female                51          39 
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AGE DISTRIBUTION (n=130) 
The study population were categorised based on their age . The obtained results are 
shown in the below table. The most predominant age group was young adulthood which 
accounts for about 36% of the overall study population. 
Sl.no Age Male Female No of patients Percentage 
1 Early adulthood 
  (19-35) 
23 19 42 32% 
2 Adulthood 
   (35-50) 
23 19 42 32% 
3 Young adulthood 
     (51-65) 
33 13 46 36% 
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  In our study most of the patients were belonging to young adulthood and males were 
more compared to females . A study conducted by Mintzer et al(23) in 2012 revealed that 
when patients were categorised into age groups, there was a very significant trend to 
prescribe AEDs at a higher rate with increasing age . Male patients were significantly more 
likely to be started on an AED than female patients . 
 
CONCOMITANT DISEASES (n=130) 
The co-morbid conditions of the epileptic patients were analyzed and the study 
population revealed that concomitant diseases like hypertension, diabetes and thyroid 
disorders were significant. 
S.No Concomitant disease No. Of patients (%) 
1 Hypertension 37(28) 
2 Diabetes 24(18) 
3 Dislipidemia 4(3) 
4 Thyroid disorders 7(5) 
5 Parkinsonism 2(1.5) 
6 Old CVA 4(3) 
7 Infections 8(6) 
8 Renal disorders 3(2) 
9 Respiratory disorders 4(3) 
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    In our study , out of 130 patients 37(38%) were having hypertension and 24(18%) were 
having diabetes . Similar study conducted by  R.M Vivango-Hidalgo et al(4) in 2016 revealed 
that PWE have been described to have more hypertension and diabetes than the general 
population, but that finding is inconsistent and both diagnoses are considered risk factors of 
stroke, a common etiology of epilepsy 
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CONCURRENT DRUGS PRESCRIBED (n=130) 
The concurrent drugs prescribed for epilepsy patients were also analysed in order to 
understand the rationality of prescription. 
 
DRUGS No. of  patients Percentage(%) 
Antidiabetic drugs 22 16 
NSAID’s 40 31 
Proton pump inhibitors 116 89 
Antibiotics 66 51 
Antiemetics 76 58 
Antihyperlipidemic 68 52 
Antihistamines 27 20 
Antihypertensive  34 26 
Cardiovascular drugs 16 12 
Anti thyroid 10 8 
Antiparkinsons 3 2 
Antideppressant 2 1.5 
Insulin 16 12 
Corticosteroids 9 7 
mucolytics 12 9 
others 63 48 
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                      Proton pump inhibitors (89%) were the major category on concurrent drugs 
prescribed, followed by antiemetics (58%) and antihyperlipidemics(52%). 
                   While statins are commonly used for secondary prevention of cardiovascular disease  
even in the setting of normal cholesterol levels, we excluded any patient with a history of 
coronary diseases from this portion of the analysis, so it is unlikely that many statin 
prescriptions in this study population were for this purpose. 
16
31
89
51
58
52
20
26
12
8
2
1.5
12
7
9
48
0 20 40 60 80 100
Antidiabetic drugs
NSAID’s
Proton pump inhibitors
Antibiotics
Antiemetics
Antihyperlipidemic
Antihistamines
Antihypertensive
Cardiovascular drugs
Anti thyroid
Antiparkinsons
Antideppressant
Insulin
Corticosteroids
mucolytics
others
Concomitant drugs prescribed (n=130)
Results and discussion 
 
A prospective, observational study on prevalence of cardiovascular risk factors and  
statin use in patients with epilepsy and  assessment of quality of life   40 
 
                     A study conducted by mintzer et al 2015(23) revealed that  once patients receive new 
AED therapy forseizures, those prescribed EIAEDs are almost 50% more likely to be 
subsequently started on lipid-lowering therapy than those who receive non-inducing AEDs. 
TYPES OF SEIZURES (n=130) 
 
Disease Characteristics Description n (%) 
n=130 
Number of 
patients 
Percentage(%) 
Type of Seizures Partial Seizures  76 58 
Simple Partial Seizure  19 14 
Complex Partial Seizures  17 13 
Partial Seizures with secondary generalization 40 31 
Generalized Seizures  54 42 
Generalized tonic clonic  49 37.5 
Absence Seizures  1 0.76 
Myoclonic Seizures  4 3.5 
 
         The majority of the patients were diagnosed with generalied tonic clonic seizures 
followed by patients diagnosed with partial seizures with secondary generalisation. 
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DRUGS PRESCRIBED FOR EPILEPSY (n=130) 
DRUGS No. of patients Percentage(%) 
Levetiracetam  110 84 
Sodium valproate 17 13 
Phenytoin  14 12 
Oxcarbazepine  14 12 
Fosphenytoin  42 32 
Divalproex  11 8 
Clobazam  27 20 
Midazolam  21 16 
Clonazepam  20 15 
Lacosamide  32 24 
Phenobarbitone  4 3 
Carbamazepine  11 8 
Zonisamide  3 2 
Lorazepam  2 1.5 
Diazepam  2 1.5 
Topiramate  5 3 
 
Results and discussion 
 
A prospective, observational study on prevalence of cardiovascular risk factors and  
statin use in patients with epilepsy and  assessment of quality of life   42 
 
 
 
                There are many drugs prescribed for epilepsy ,of which levetiracetam was the most 
prescribed drug having prescribed to over 85% of the patients followed by fosphenytoin 
(32%) and lacosamide (24%). 
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DRUG INTERACTION IN THE PRESCRIPTION(n=130) 
 
 
Sl.no Interaction drugs Inferences  severity No.of 
patients 
1 Atorvastatin+ pantoprazole Increase the blood levels and 
effects of atorvastatin 
Moderate  15 
2 Clopidogrel + pantoprazole Decrease effects of 
clopidogrel 
Moderate  14 
3 Aspirin + telmisartan Decrease effects of 
telmisartan in decreasing BP 
Moderate  3 
4 Aspirin + clopidogrel May cause unusual bleeding  Moderate  4 
5 Aspirin + insulin Hypoglycemia may be 
potentiated 
Moderate  1 
6 
 
 
Ketorolac + amitriptylline Concurrent use may lead to 
incresed risk of bleeding 
Major  1 
7 Phenytoin + clopidogrel Increase effect of hepatic 
CYP3A4 metabolism 
Moderate  4 
8 Phenytoin + atorvastatin Decrease effect of hepatic 
CYP3A4 metabolism 
Moderate  6 
9 Fosphenytoin + midazolam Concurrent use result in 
decreased efficacy of 
midazolam 
Moderate  7 
10 Divalproex + fosphenytoin Concurrent use may result in 
altered valproate or 
phenytoin level 
Moderate  3 
11 Clobazam + paracetamol Additive respiratory 
depression 
Moderate  1 
12 Levetiracetam + paracetamol Decreases level of 
paracetamol 
Minor  1 
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POLYPHARMACY AND MONOTHERAPY CATOGORISATION 
(n=130) 
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65%
MONOTHERAPY
POLYPHARMACY
SL 
NO 
CATOGORY NO OF PATIENTS PERCENTAGE 
1 POLYPHARMACY 85 65% 
 
2 MONOTHERAPY 
 
45 35% 
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ASSESSMENT OF STATIN USE (n=130) 
1 Patients prescribed with statins 68 52% 
2 Patients with lipid profile available 
and prescribed with statins. 
51 39% 
3 Patients with no lipid profile 
available and prescribed with statins. 
17 13% 
 
              Out of the 130 patients 68 patients were prescribed with statins and 51 patients had 
done lipid profile.  Since 52% of the study population was  prescribed with statins . A study 
conducted by Ane Gedde-Dahl et al(29) in 2012 revealed that the study showed high 
prevalence of co-prescription of   statins with AEDs in Norwegian clinical practice. 
 
        CARDIOVASCULAR RISK ASSESSMENT USING FRAMINGHAM 
RISK(n=130) 
 
Sl no Cardiovascular risk No of patients Percentage % 
1 High risk 22 17% 
2 Intermediate risk 5 4% 
3 Low risk 24 19% 
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    The Framingham risk score was used to analyze the 10 – year cardiovascular risk of 
the patients. Risk factors included were age, sex, total cholesterol (mg/dl), high-density 
lipoprotein cholesterol (HDLc, mg/dl), DBP and SBP (mmHg), diabetes and smoking.Risk 
was categorized as low (<5%), intermediate (5%_9.9%) and high (≥10%).In our study 
patients with epilepsy showed prevalence of hypertension and diabetes. It was found that this 
group had more prevalence of diabetes. Smoking was categorised in three groups: current , 
former and never smokers. Dislipidimia was also prevalent in a few patients. 
Patients who was on high risk had high prevalence of hypertension ,diabetes and smoking . 
 
 
     
      There are some limitations. Since lipid profile was a important factor to assess the 
cardiovascular risk ,the unavailability of lipid pfofile was a limitation faced during the study. 
No information was available about lipid levels or cardiovascular risk before AED or statin 
treatment. 
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       A study conducted by Etminan M et al(29) revealed that the use of statins not only has 
proven efficacy for CVDs, but also provides an antiepileptogenic effect and may decrease the 
risk of epilepsy hospitalization in cardiovascular patients . 
QUALITY OF LIFE ASSESSMENT 
   The QOLIE-10 questionnaire was used to measure the overall quality of life in study 
sample. The QOLIE-10-P screening questionnaire scoring instructions was obtained from the 
author. The QOLIE-10-P is a patient weighted questionnaire ,which provides a weighted final 
score . Higher scores represent better quality of life.  
QUALITY OF LIFE STRATIFIED BY AGE GROUP(n=130) 
   The final QOL score was stratified by age group and the patients belonging to early 
adulthood was having a relatively high QOL. 
Sl no Age groups Mean QOL score SD 
1 Early adulthood 
(19-35) 
73.74 12.6289 
2 Adulthood  
(35-50) 
61.38 5.1336 
3 Late  adulthood 
(50-65) 
33.87 1.2304 
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      The QOL score obtained for different age groups were statistically analysed by using 
one-way ANOVA. The f-ratio value is 13.77851. The p-value is .030762. The result is 
significant at p<.05.this means that the difference between QOL scores obtained by different 
age groups are statistically significant. 
 QUALITY OF LIFE SCORES STRATIFIED BY GENDER 
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Sl no Gender  QOL score 
1 Male  62.58 
2 Female  50.07 
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The younger males had a good QOL score and elder females had the worst quality of 
life score. 
COMPARISON OF QOL SCORE BETWEEN GENDER AND 
DIFFERENT AGE GROUP (n=130) 
 
Sl no                Age group  
 
Gender  
Earlyadulthood 
(19-35) 
Adulthood  
(35-50) 
Late adulthood 
(50-65) 
1 Male  78.13 71.49 38.14 
2 Female  69.35 52.25 28.62 
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           Out of 130 patients 79(61%) were males and 51(39%) were females. In our study male 
patients had better quality of life score than females. Increasing age also showed greater 
impairment of QOL. Prakruti Patel et al in 2017(5) revealed that that males had higher QOL 
score compared to females as it was found that male enrolled in study had higher education 
than females, thus contributing to better QOL. We also noted that QOL score was found to 
decrease with increasing age most probably due to chronicity of disease and drug therapy 
thus effecting QOL. 
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COMPARISON OF MEAN SCORE OF QOL BETWEEN 
POLYPHARMACY AND MONOTHERAPY (n=130) 
 
   According to a recent study conducted by Halley B Alexander et al in 2017(11) 
revealed that patients on polypharmacy were almost twice likely to have continuing seizures 
than monotherapy patients. They also had worse QOL scores , most prominently on epilepsy 
effect and role functioning domains.  
The QOL score obtained by patients receiving polypharmacy and monopharmacy 
were statistically analysed using unpaired student t-test. The p-value  obtained was 0.634,ie 
p-value is greater than .05. This means that the difference is not statistically significant 
 
     
 
 
Sl 
no 
Age groups Polypharmacy  Monopharmacy  
1 Early 
adulthood 
19-35 
64.81 82.67 
2 Adulthood  
35-50 
 
58.24 65.50 
3 Late adulthood 
50-65 
32.51 34.35 
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  Out of 130 patients 85 were on polytherapy and 45 were on monotherapy. The 
adverse drug reactions caused by AEDs can be the cause of poor QOL of patients on 
polytherapy. A study conducted by R K Surekha et al in the year 2015(12) revealed that 
patients who were on a single drug (monotherapy) had a much better QOL than the patients 
on more than one drug (polytherapy). The type of drug therapy followed by a patient with 
epilepsy plays a very important role. Patients who were on monotherapy had a better quality 
of life mainly because of the lesser side effects as compared with those on polytherapy.  
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SUMMARY 
The work entitled ” A prospective, observational study on prevalence of 
cardiovascular risk factors and  statin use in patients with epilepsy and  assessment of quality 
of life” was conducted in the department of neurology of a 1000 bedded multispecialty 
hospital .The study protocol was prepared and submitted to the ethical committee of the 
hospital and official approval was obtained to carry out the study after ensuring the scope of 
the study in the department of neurology of the study hospital. After receiving the official 
approval, the study was conducted for a period for a period of  eight months from December 
2017 to July 2018. The results obtained from the study population are summarized as 
follows: 
 The study population consisted of 130 patients with epilepsy as per the 
inclusion criteria. 
 There were 79(61%) male patients and 51 (39%) female patients included in 
the study. 
 The maximum number of patients were between the age group of 51-65 (36%) 
followed by age group of 35-50 (32%). 
 Hypertension (28%) and Diabetes(18%) were the major comorbid conditions 
among epilepsy patients. 
 The majority of the patients were diagnosed with generalised tonic clonic 
seizures(37.5%), followed by partial seizures with secondary 
generalisation(31%). 
 Proton pump inhibitors (89%), antibiotics (51%), lipid lowering agents (52%) 
and antiemetics (58%) were the major category of drugs prescribed. 
 Antidiabetic drugs (16%) and antihypertensive drugs (26%) dr were major 
category of drugs prescribed since high prevalence of hypertension and 
diabetes was observed as comorbidity in the study population. 
 Levetiracetam (84%),was the maximum prescribed antiepileptic drug in the 
study department, followed by fosphenytoin (32%),lacosamide (24%) and 
clobazam (20%). 
 The drug interaction between atorvastatin and pantoprazole was the mostly 
recorded drug interaction,which was observed in 15 patients with moderate 
severity. 
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 In the study population 85(65%) patients were receiving polypharmacy and 
45(35%) patients were receiving monotherapy. 
 In the study population 68(52%) of patients were receiving lipid lowering 
drugs, in which 51(39%) patients were having lipid profile data. 
 In the study population 22(17%) patients were with high cardiovascular risk 
and 24 (19%) patients were with low cardiovascular risk. 
 The patients belonging to early adulthood was having a relatively high QOL. 
 The younger males had a good QOL score and elder females had the worst 
quality of life score. 
 Out of 130 patients 79(61%) were males and 51(39%) were females. In our 
study male patients had better quality of life score than females. Increasing 
age also showed greater impairment of QOL. 
 Patients who were on monotherapy had a better quality of life mainly because 
of the lesser side effects as compared with those on polytherapy. 
Conclusion 
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CONCLUSION 
         The health related quality of life includes health factors that both positively and 
negatively impact the quality of life. There is a lack of knowledge regarding the health related 
quality of life among individuals living with epilepsy at the community level and the factors 
associated with poor quality of life in a rural population. The protective as well as risk factors 
for the poor quality of life if known can help direct future research to formulate more 
effective strategies to help individuals and their patients to cope with the disease thus 
improving their quality of life and decrease the burden on individuals, their families and the 
community. 
  The majority of the patients included in the study were males (61%) and females(39%). 
Most of the patients were males and patients belonged to the age group of 50-65 years. 
Younger males had better QOL scores and elder females had the worst QOL scores. The 
increase in the age showed increase in the impairment of quality of life. Patients receiving 
monopharmacy had better QOl scores when compared to polypharmacy group. This may be 
due to the impact of side effects of antiepileptic drugs used. 
  The use of lipid lowering drugs like statins was found to be higher in patients with epilepsy 
regardless of the serum lipid levels. Among patients prescribed with statins most of the 
patients were at low risk of cardiovascular disease. Recent studies suggest that enzyme 
inducing AEDs may alter the serum cholesterol levels. So switching over to non-enzyme 
inducing AEDs may help in stabilising the serum lipid levels and CVD risk of patients with 
epilepsy. 
 
 
Future outlook 
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FUTURE OUTLOOK 
       The  present study covers the health related quality of life and assess the prevalence of 
cardiovascular risk factors and statin use in patients with epilepsy. QOLIE-10-P questionnaire 
which is an abbreviated quality of life questionnaire for epilepsy was administered to each 
patient to measure their overall QOLIE-10 score. 
        The possible interventions can be divided into interventions to improve the control over 
epilepsy, to decrease the side effects of the medications, to improve the coping skills of 
individuals with epilepsy and better management of comorbidities. Interventions to improve 
control over epilepsy can include changing medications to newer anti-epileptic medications, 
which have fewer side effects but cost is a major limitation. The State run Public Health 
System can play an important role in addressing this issue. 
      Future aspects of the study may be include interviewing patients in multiple stages ie, 
atthe time of admission, during recovery periods as 3rd month, 6th month etc. Such studies can 
evaluate the improvements achieved due to the interventions made by the pharmacist. There 
is also a great need for further research in to interventions for occupational therapy, as 
socioeconomic status and occupation were factors that had influence on the quality of life. 
     Appropriate AED selection preferably monotherapy and careful evaluation of drug side 
effects play a crucial role in achieving the ultimate target goals of seizure freedom and 
optimal quality of life among patients with epilepsy. 
     Ideally, a cardiovascular risk score should be calculated in those receiving no treatment at 
the start of and during the study. Physicians should use clinical judgement to decide on 
further treatment of CVRFs in PWE who are below the recommended risk threshold for 
treatment and should consider lipid abnormalities a potential side-effect of EIAEDs. Other 
therapy options may need to be evaluated before starting lipid-lowering treatment. 
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Today’s Date    _______ / ______ / ______  Your Name_________________________ 
  mm           dd               yy Your Age: ___   ___ years 
 
 
INSTRUCTIONS 
The QOLIE-10-P is a brief survey of health-related quality of life for adults with epilepsy. There are 10 questions 
about health and daily activities, one question about how much distress you feel about problems and worries 
related to epilepsy, and a review of what bothers you most. This questionnaire should be completed only by the 
person who has epilepsy (not a relative or friend) because no one else knows how YOU feel.  
 
Answer every question by circling the appropriate number (1, 2, 3...). If you are unsure about how to answer a 
question, please give the best answer you can and write a comment or explanation on the side of the page. 
These notes may be useful if you discuss the QOLIE-10-P with your doctor. Completing the QOLIE-10-P before 
and after treatment changes may help you and your doctor understand how the changes have affected your life. 
 
 
These questions are about how you have been FEELING and the types of problems you have been having 
during the past 4 weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling. 
How much of the time during the past 4 weeks… (Circle one number on each line) 
 
 
All 
of the 
time 
Most 
of the 
time 
A good bit 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
1. Did you have a lot of energy? 
 
1 2 3 4 5 6 
 
2. Have you felt downhearted and low? 
 
1 2 3 4 5 6 
 
3. How much of the time during the past 4 weeks your epilepsy 
    or antiepileptic drugs have caused trouble with  
driving (or other transportation) A great deal A lot Somewhat Only a little Not at all 
 
 
1 2 3 4 5 
During the past 4 weeks… 
Not at all 
bothersome    
Extremely 
bothersome 
 
4. How much do your work limitations bother you? 
 
1 2 3 4 5 
 
5. How much do your social limitations bother you? 
 
1 2 3 4 5 
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During the past 4 weeks… 
Not at all 
bothersome    
Extremely 
bothersome 
 
6. How much do your memory difficulties bother you? 
 
1 2 3 4 5 
 
7. How much do physical effects of antiepileptic drugs bother 
you? 
 
1 2 3 4 5 
 
8. How much do psychological effects of antiepileptic 
drugs bother you? 
1 2 3 4 5 
 
Very 
afraid 
Somewhat 
afraid 
Not very 
afraid 
Not afraid 
at all 
 
9. How afraid are you of having a seizure during the next 4 weeks? 
 
1 2 3 4 
 
10. How has your QUALITY OF LIFE been during the past 4 weeks 
(that is, how have things been going for you)? 
 
   
(Circle one number 
on the ladder) 
 
Very good: 
could hardly have been 
better 
 1 
    
 Pretty good  2 
    
 Good & bad about equal  3 
    
 Pretty bad  4 
    
 
Very bad: 
could hardly have been 
worse 
 5 
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Reviewing all the questions you have answered above, consider the overall impact of these problems on your 
quality of life in the past 4 weeks. (Circle one number) 
 Not at all Somewhat Moderately A lot Very much 
11. How much does the state of your epilepsy-related  
quality of life distress you overall? 
1 2 3 4 5 
 
 
 
Considering ALL the questions you have answered, please indicate the areas related to your epilepsy that are 
most IMPORTANT to you NOW. 
 
12. Number the following topics from ‘1’ to ‘7’ with ‘1’ corresponding to the most important topic and ‘7’ to the 
least important one. Please use each number only once. 
 
└──┘ 
A. Energy (tiredness) 
└──┘ 
B. Emotions (mood) 
└──┘ 
C. Daily activities (work, driving, social & other activities) 
└──┘ 
D. Mental function (thinking, concentrating, memory) 
└──┘ 
E. Medication effects (physical, mental) 
└──┘ 
F. Worry about seizures (impact of seizures) 
└──┘ 
G. Overall quality of life 
 
 
 
 
 
 
 
This copy of the QOLIE-10-P is provided by the QOLIE Development Group.We wish you success in 
living your life with epilepsy! 
QOLIE-10-P© All versions copyright by the QOLIE Development Group. All rights reserved. 
 
Quality of Life In Epilepsy: QOLIE-10-P 
SCORING INSTRUCTIONS 
 
Provided by the QOLIE Development Group 
Contact person: joyce.cramer@gmail.com 
 
QOLIE-10-P© All versions copyright by the QOLIE Development Group. All rights reserved. 
 
The QOLIE-10 screening questionnaire includes 11 questions. Three questions have 
opposite response sets, requiring reverse-scoring. The scoring should be calculated so 
that all positive responses are lower numbers and all negative responses are higher 
numbers.  
[The QOLIE-10-P includes 11 questions, with items 1-10 identical to the QOLIE-10.] 
 
Patients with lowest scores have the least problems. Thus, some items must be 
reverse-scored to reflect higher quality of life: 
Items scored with "1" as best should be scored in "reverse":   
Items scored with "1" as worst should be scored as indicated:  
 
  1 2 3 4 5 6 Item 
Score  
 
 1 100 80 60 40 20 0   
 2 0 20 40 60 80 100   
 3 0 25 50 75 100    
 4 100 75 50 25 0    
 5 100 75 50 25 0    
 6 100 75 50 25 0    
 7 100 75 50 25 0    
 8 100 75 50 25 0    
 9 0 33.3 66.7 100     
 10 100 75 50 25 0    
       Subtotal =   
      Mean Score=Subtotal ÷ 10 =  
Distress       
 11 100% 75% 50% 25% 10% Distress Score (%)            % 
      Final Score (Mean x Distress%)  
 
CALCULATIONS: 
1. The Mean Score is the sum of scores for all questions divided by the number of 
items answered.  
2. The Mean Score is multiplied by the response for Item # 11 to create the final 
“weighted” score. 
3. If one item is missing, the score may be imputed based on the 9 responses. If 
more than one item is missing, the instrument is not valid. 
4. Higher scores represent better quality of life. 
 
